CRAFA
PEPTIDE & COMPOUND ANALYSIS

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0194
Issued: 2026-09-20

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

PRODUCT IDENTIFICATION

PRODUCT Cagrilintide + Semaglutide 5mg/5mg	SKU / INTERNAL CODE CRF-2026-0194	PRESENTATION Lyophilised powder, 5mg/5mg vial
BATCH NUMBER CRF-2026-0194	SAMPLE RECEIVED 2026-09-13	PRODUCTION DATE 2026-09-08
ANALYSIS DATE 2026-09-18	EXPIRY / RETEST DATE 2028-09-18	MOLECULAR FORMULA Blend (C194H312N54O59S2 + C187H291N45O59)
MOLECULAR WEIGHT (G/MOL) N/A	CAS N/A	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Thermo Q-Exactive	COLUMN C4 2.1×100mm	COLUMN TEMPERATURE 60°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B ACN	FLOW RATE 0.3 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 5 µL	SAMPLE CONCENTRATION 0.5 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 12.1 / 12.8 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.3%	PASS
Identity (LC-MS)	4410.0 & 4114.6 ±2%	Obs: 4410.4 / 4114.9 [M+H]+	PASS

Test	Acceptance Criteria	Result	Verdict
Quantity found	95.0–105.0%	9.89 mg (98.9%)	PASS
Endotoxin	<1.0 EU/mg	<0.25 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Category: Specialty. Sample conforms to label claim and Gold panel acceptance criteria.

crafa

CRAFA